ProMIS Neurosciences (PMN) Amortization of Deferred Charges (2021 - 2022)
ProMIS Neurosciences' (PMN) quarterly Amortization of Deferred Charges came in at -$5192.0 in Q4 2022, down 104.17% YoY from $124460.0 in Q4 2021, and down 72.26% on a QoQ basis from -$3014.0 in Q3 2022.
ProMIS Neurosciences (PMN) Amortization of Deferred Charges (2021 - 2022) Analysis & Trends
ProMIS Neurosciences (PMN) has 2 years of Amortization of Deferred Charges data on file, last reported at -$5192.0 in Q4 2022.
- Quarterly Amortization of Deferred Charges fell 104.17% year-over-year to -$5192.0 in Q4 2022, while the trailing twelve-month figure through Dec 2022 was $246817.0 (changed N/A YoY) and the FY2022 annual result came in at $241854.0, down 33.92% from the prior year.
- Amortization of Deferred Charges fell to -$5192.0 in Q4 2022, from -$3014.0 in the prior quarter.
- In the past five years, Amortization of Deferred Charges ranged from a high of $144154.0 in Q3 2021 to a low of -$5192.0 in Q4 2022.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | ProMIS Neurosciences | 132.34 Mn | 78.87 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2022 | -5,192.00 |
| Dec 31, 2022 | -5,192.00 |
| Sep 30, 2022 | -3,014.00 |
| Sep 30, 2022 | -3,014.00 |
| Mar 31, 2022 | 130,563.00 |
| Mar 31, 2022 | 130,563.00 |
| Dec 31, 2021 | 124,460.00 |
| Dec 31, 2021 | 124,460.00 |
| Sep 30, 2021 | 144,154.00 |
| Sep 30, 2021 | 144,154.00 |